Inventor · disambiguated record
Ivan M. Borrello
Also filed as: BORRELLO IVAN · BORRELLO IVAN M · BORRELLO IVAN MARQUES
12 granted patents·18 pending applications·187 citations·filing 1999–2022
91Inventor score
Files withUNIV JOHNS HOPKINS17UNIV JOHNS HOPKINS MED6WINDMIL THERAPEUTICS INC4MERIDIAN THERAPEUTICS INC2LEVITSKY HYAM I1
Top patents by PatentIndex Score
30 records- 0196US9687510B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2015·Granted Jun 27, 2017·28 cites·15 claims
- 0295US10172887B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2017·Granted Jan 8, 2019·10 cites·19 claims
- 0395US8012469B2Universal GM-CSF expressing bystander human K562 cell lineUNIV JOHNS HOPKINS MED·Filed 2008·Granted Sep 6, 2011·29 cites·17 claims
- 0494US6464973B1Universal GM-CSF expressing bystander human K562 cell lineUNIV JOHNS HOPKINS MED·Filed 1999·Granted Oct 15, 2002·96 cites·21 claims
- 0589US7390483B2Universal GM-CSF expressing bystander human K562 cell lineUNIV JOHNS HOPKINS MED·Filed 2006·Granted Jun 24, 2008·9 cites·21 claims
- 0686US11160830B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2018·Granted Nov 2, 2021·1 cites·13 claims
- 0784US8383096B2Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccineUNIV JOHNS HOPKINS MED·Filed 2010·Granted Feb 26, 2013·5 cites·11 claims
- 0882US10406178B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2017·Granted Sep 10, 2019·2 cites·20 claims
- 0981US2023000919A1Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 1078US7740871B2Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccineUNIV JOHNS HOPKINS MED·Filed 2003·Granted Jun 22, 2010·6 cites·18 claims
- 1177US11406666B2Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2019·Granted Aug 9, 2022·0 cites·41 claims
- 1277US2022016172A1Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditionsUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 1374US11478548B2Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapyUNIV JOHNS HOPKINS·Filed 2016·Granted Oct 25, 2022·1 cites·8 claims
- 1471US2023210990A1Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) thereapyUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 1570US2023016031A1Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) thereapyUNIV JOHNS HOPKINS·Filed 2022·Application pending·0 cites
- 1663US2020171089A1Use of Post-Transplant Cyclophosphamide Treated Allogenic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor ImmunityWINDMIL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1763US2022257650A1MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPYWINDMIL THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1862US2011223146A1Methods for preparation and use of marrow infiltratng lymphoctyes (mils)UNIV JOHNS HOPKINS·Filed 2009·Application pending·0 cites
- 1960US2015320798A1Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor ImmunityUNIV JOHNS HOPKINS·Filed 2013·Application pending·0 cites
- 2060US2021154233A1MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPYWINDMIL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2160US2024316103A1Compositions and methods of treating plasma cell disorders including multiple myeloma with a vaccine composition and myeloma-specific car-t cellsMERIDIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2259US9468643B2PDE5 inhibitor compositions and methods for immunotherapyUNIV JOHNS HOPKINS·Filed 2014·Granted Oct 18, 2016·0 cites·16 claims
- 2359US2024238342A1A Vaccine Composition for Plasma Cell Disorders Including Multiple Myeloma and Methods to Induce Immunity Using SameMERIDIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2459US2009074796A1Pde5 inhibitor compositions and methods for immunotherapyUNIV JOHNS HOPKINS·Filed 2006·Application pending·0 cites
- 2556US2011287058A1Universal GM-CSF Expressing Bystander Human Cell LineLEVITSKY HYAM I·Filed 2011·Application pending·0 cites
- 2655US2017224691A1Pde inhibitors in immunotherapyUNIV JOHNS HOPKINS·Filed 2016·Application pending·0 cites
- 2753US2024091257A1Use of activated t-cells to enhance anti-tumor activity of bispecific antibodies or bitesUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 2852US2002037282A1Universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and useUNIV JOHNS HOPKINS MED·Filed 2001·Application pending·0 cites
- 2941US2018185434A1Immune checkpoint chimeric antigen receptors therapyUNIV JOHNS HOPKINS·Filed 2016·Application pending·0 cites
- 3040US2019330306A1Compositions and Methods for Modulating the Immune SystemWINDMIL THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ivan M. Borrello files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →